{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:09:39Z","timestamp":1792206579215,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Attention-deficit hyperactivity disorder (ADHD) is becoming more commonly diagnosed in women, consequently, more women of reproductive age are taking ADHD medication, such as dexamphetamine. However, the safety associated with continuing or ceasing dexamphetamine during pregnancy is unclear. This study investigates outcomes associated with the continuation of dexamphetamine during pregnancy compared to those who ceased or were unexposed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A population-based retrospective cohort of women from Western Australia who had been dispensed dexamphetamine during pregnancy and gave birth between 2003 and 2018. Women had either continued to take dexamphetamine throughout pregnancy (continuers, <jats:italic>n<\/jats:italic>\u2009=\u2009547) or ceased dexamphetamine before the end of the second trimester (ceasers, <jats:italic>n<\/jats:italic>\u2009=\u2009297). Additionally, a matched (1:1) comparison group of women who were dispensed an ADHD medication prior to pregnancy but not during pregnancy (unexposed) was included in the study (<jats:italic>n<\/jats:italic>\u2009=\u2009844). Multivariable generalised linear models were used to compare maternal and neonatal health outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared to continuers, ceasers had greater odds of threatened abortion (OR: 2.28; 95%CI: 1.00, 5.15; <jats:italic>p<\/jats:italic>\u2009=\u20090.049). The unexposed had some benefits compared to the continuers, which included lower risk of preeclampsia (OR: 0.58; 95%CI: 0.35, 0.97; <jats:italic>p<\/jats:italic>\u2009=\u20090.037), hypertension (OR: 0.32; 95%CI: 0.11, 0.93; <jats:italic>p<\/jats:italic>\u2009=\u20090.036), postpartum haemorrhage (OR: 0.57; 95%CI: 0.41, 0.80; <jats:italic>p<\/jats:italic>\u2009=\u20090.001), neonatal special care unit admittance (OR: 0.16; 95%CI: 0.12, 0.20; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and fetal distress (OR: 0.73; 95%CI: 0.54, 0.99; <jats:italic>p<\/jats:italic>\u2009=\u20090.042).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Continuing dexamphetamine throughout pregnancy was not associated with an increase in adverse neonatal and maternal health outcomes compared to ceasing. Ceasing dexamphetamine during pregnancy was associated with increased odds of threatened abortion compared with continuing dexamphetamine. However, this is something that requires further investigation due to the small sample size, difficulties examining timing, and the inability to examine spontaneous abortions. The unexposed showed some benefits compared to the continuers, suggesting that where possible the cessation of dexamphetamine prior to pregnancy may be advisable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00737-024-01450-4","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T05:05:01Z","timestamp":1709269501000},"page":"785-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Investigating maternal and neonatal health outcomes associated with continuing or ceasing dexamphetamine treatment for women with attention-deficit hyperactivity disorder during pregnancy: a retrospective cohort study"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-4415","authenticated-orcid":false,"given":"Danielle J.","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5746-5680","authenticated-orcid":false,"given":"Caitlin S.","family":"Wyrwoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2982-2169","authenticated-orcid":false,"given":"David B.","family":"Preen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0841-2216","authenticated-orcid":false,"given":"Erin","family":"Kelty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"issue":"2","key":"1450_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.15585\/mmwr.mm6702a3","volume":"67","author":"KN Anderson","year":"2018","unstructured":"Anderson KN, Ailes EC, Danielson M, Lind JN, Farr SL, Broussard CS, Tinker SC (2018) Attention-deficit\/hyperactivity disorder medication prescription claims among privately insured women aged 15\u201344 years \u2014 United States, 2003\u20132015. MMWR Morb Mortal Wkly Rep 67(2):66\u201370. https:\/\/doi.org\/10.15585\/mmwr.mm6702a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1450_CR2","doi-asserted-by":"publisher","unstructured":"Andrade C (2018) Risk of major congenital malformations associated with the use of methylphenidate or amphetamines in pregnancy. J Clin Psychiatry 79(1). https:\/\/doi.org\/10.4088\/JCP.18f12108","DOI":"10.4088\/JCP.18f12108"},{"issue":"6","key":"1450_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40264-014-0168-5","volume":"37","author":"FMC Besag","year":"2014","unstructured":"Besag FMC (2014) ADHD treatment and pregnancy. Drug Saf 37(6):397\u2013408. https:\/\/doi.org\/10.1007\/s40264-014-0168-5","journal-title":"Drug Saf"},{"issue":"1","key":"1450_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2431-5-13","volume":"5","author":"EM Blair","year":"2005","unstructured":"Blair EM, Liu Y, de Klerk NH, Lawrence DM (2005) Optimal fetal growth for the caucasian singleton and assessment of appropriateness of fetal growth: an analysis of a total population perinatal database. BMC Pediatr 5(1):13\u201313. https:\/\/doi.org\/10.1186\/1471-2431-5-13","journal-title":"BMC Pediatr"},{"key":"1450_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/CLEP.S72906","volume":"7","author":"SP Bro","year":"2015","unstructured":"Bro SP, Kjaersgaard MIS, Parner ET, S\u00f8rensen MJ, Olsen J, Bech BH, Vestergaard M (2015) Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol 7:139\u2013147. https:\/\/doi.org\/10.2147\/CLEP.S72906","journal-title":"Clin Epidemiol"},{"issue":"1","key":"1450_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/ije\/dyac180","volume":"52","author":"X Camacho","year":"2023","unstructured":"Camacho X, Zoega H, Gomes T, Schaffer AL, Henry D, Pearson S-A, Havard A (2023) The association between psychostimulant use in pregnancy and adverse maternal and neonatal outcomes: results from a distributed analysis in two similar jurisdictions. Int J Epidemiol 52(1):190\u2013202. https:\/\/doi.org\/10.1093\/ije\/dyac180","journal-title":"Int J Epidemiol"},{"issue":"6","key":"1450_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/AOG.0000000000002362","volume":"130","author":"JM Cohen","year":"2017","unstructured":"Cohen JM, Hern\u00e1ndez-D\u00edaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Huybrechts KF (2017) Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol (New York 1953) 130(6):1192\u20131201. https:\/\/doi.org\/10.1097\/AOG.0000000000002362","journal-title":"Obstet Gynecol (New York 1953)"},{"issue":"1","key":"1450_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00228-022-03428-6","volume":"79","author":"JM Cohen","year":"2023","unstructured":"Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad \u00d8 (2023) Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010\u20132019. Eur J Clin Pharmacol 79(1):173\u2013180. https:\/\/doi.org\/10.1007\/s00228-022-03428-6","journal-title":"Eur J Clin Pharmacol"},{"key":"1450_CR9","unstructured":"Council NHaMR (2007) The national statement on ethical conduct in human research. https:\/\/www.nhmrc.gov.au\/sites\/default\/files\/documents\/attachments\/National%20Statement\/e72.pdf"},{"key":"1450_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.genhosppsych.2021.09.003","volume":"73","author":"EA Damer","year":"2021","unstructured":"Damer EA, Edens MA, van der Loos MLM, van Esenkbrink J, Bunkers I, van Roon EN, ter Horst PGJ (2021) Fifteen years\u2019 experience with methylphenidate for attention-deficit disorder during pregnancy: effects on birth weight, Apgar score and congenital malformation rates. Gen Hosp Psychiatry 73:9\u201315. https:\/\/doi.org\/10.1016\/j.genhosppsych.2021.09.003","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"1450_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.4088\/JCP.15m10083","volume":"77","author":"O Diav-Citrin","year":"2016","unstructured":"Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C, Beck E, Ornoy A (2016) Methylphenidate in pregnancy: a multicenter, prospective, comparative, observational study. J Clin Psychiatry 77(9):1176\u20131181. https:\/\/doi.org\/10.4088\/JCP.15m10083","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"1450_CR12","doi-asserted-by":"publisher","first-page":"e47404","DOI":"10.1371\/journal.pone.0047404","volume":"7","author":"JL Ebejer","year":"2012","unstructured":"Ebejer JL, Medland SE, van der Werf J, Gondro C, Henders AK, Lynskey M, Duffy DL (2012) Attention deficit hyperactivity disorder in Australian adults: prevalence, persistence, conduct problems and disadvantage. PLoS ONE 7(10):e47404\u2013e47404. https:\/\/doi.org\/10.1371\/journal.pone.0047404","journal-title":"PLoS ONE"},{"issue":"15","key":"1450_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/bdr2.1774","volume":"112","author":"JD Garey","year":"2020","unstructured":"Garey JD, Lusskin SI, Scialli AR (2020) Teratogen update: amphetamines. Birth Defects Res 112(15):1171\u20131182. https:\/\/doi.org\/10.1002\/bdr2.1774","journal-title":"Birth Defects Res"},{"issue":"4","key":"1450_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/jech.47.4.316","volume":"47","author":"L Gill","year":"1993","unstructured":"Gill L, Goldacre M, Simmons H, Bettley G, Griffith M (1993) Computerised linking of medical records: methodological guidelines. J Epidemiol Community Health (1979) 47(4):316\u2013319. https:\/\/doi.org\/10.1136\/jech.47.4.316","journal-title":"J Epidemiol Community Health (1979)"},{"issue":"1","key":"1450_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bpobgyn.2013.08.017","volume":"28","author":"VP Glover","year":"2013","unstructured":"Glover VP (2013) Maternal depression, anxiety and stress during pregnancy and child outcome; what needs to be done. Best Pract Res Clin Obstet Gynecol 28(1):25\u201335. https:\/\/doi.org\/10.1016\/j.bpobgyn.2013.08.017","journal-title":"Best Pract Res Clin Obstet Gynecol"},{"issue":"4","key":"1450_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajog.2014.06.005","volume":"211","author":"MC Gorman","year":"2014","unstructured":"Gorman MC, Orme KS, Nguyen NT, Kent EJ, Caughey AB (2014) Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol 211(4):429. .e421-429.e427","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1450_CR17","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.4088\/JCP.12r07968","volume":"74","author":"S Grigoriadis","year":"2013","unstructured":"Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis C-L, Koren G, Ross LE (2013) The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 74(4):e321\u2013e341. https:\/\/doi.org\/10.4088\/JCP.12r07968","journal-title":"J Clin Psychiatry"},{"key":"1450_CR18","unstructured":"Guidelines for midwives notification of case attended. (2021) Perth, Western Australia Retrieved from http:\/\/ww2.health.wa.gov.au\/Articles\/J_M\/MidwivesNotification-System"},{"issue":"5","key":"1450_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/pds.3600","volume":"23","author":"KB H\u00e6rvig","year":"2014","unstructured":"H\u00e6rvig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K (2014) Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf 23(5):526\u2013533. https:\/\/doi.org\/10.1002\/pds.3600","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1450_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1467-842X.1999.tb01297.x","volume":"23","author":"CDAJ Holman","year":"1999","unstructured":"Holman CDAJ, Bass AJ, Rouse IL, Hobbs MST (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23(5):453\u2013459. https:\/\/doi.org\/10.1111\/j.1467-842X.1999.tb01297.x","journal-title":"Aust N Z J Public Health"},{"issue":"7","key":"1450_CR20","first-page":"1153","volume":"53","author":"C Humphreys","year":"2007","unstructured":"Humphreys C, Garcia-Bournissen F, Ito S, Koren G (2007) Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Physician 53(7):1153\u20131155","journal-title":"Can Fam Physician"},{"issue":"3","key":"1450_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/pds.4716","volume":"28","author":"Hy Jiang","year":"2019","unstructured":"Jiang Hy, Zhang X, Jiang Cm, Fu Hb (2019) Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 28(3):288\u2013295. https:\/\/doi.org\/10.1002\/pds.4716","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1450_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/ADM.0000000000000391","volume":"12","author":"D-R Kalaitzopoulos","year":"2018","unstructured":"Kalaitzopoulos D-R, Chatzistergiou K, Amylidi A-L, Kokkinidis DG, Goulis DG (2018a) Effect of m ethamphetamine hydrochloride on p regnancy outcome: a systematic review and meta-analysis. J Addict Med 12(3):220\u2013226. https:\/\/doi.org\/10.1097\/ADM.0000000000000391","journal-title":"J Addict Med"},{"key":"1450_CR24","doi-asserted-by":"crossref","unstructured":"Kalaitzopoulos D-R, Chatzistergiou K, Amylidi A-L, Kokkinidis DG, Goulis DG (2018b) Effect of methamphetamine hydrochloride on pregnancy outcome: a systematic review and meta-analysis. J Addict Med, 12(3)","DOI":"10.1097\/ADM.0000000000000391"},{"issue":"10","key":"1450_CR28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/ph6101221","volume":"6","author":"B K\u00e4ll\u00e9n","year":"2013","unstructured":"K\u00e4ll\u00e9n B, Borg N, Reis M (2013) The use of central nervous system active drugs during pregnancy. Pharmaceuticals 6(10):1221\u20131286. https:\/\/doi.org\/10.3390\/ph6101221","journal-title":"Pharmaceuticals"},{"key":"1450_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neubiorev.2021.01.002","volume":"124","author":"S Kittel-Schneider","year":"2021","unstructured":"Kittel-Schneider S, Quednow BB, Leutritz AL, McNeill RV, Reif A (2021) Parental ADHD in pregnancy and the postpartum period \u2013 A systematic review. Neurosci Biobehav Rev 124:63\u201377. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.01.002","journal-title":"Neurosci Biobehav Rev"},{"key":"1450_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.reprotox.2020.03.003","volume":"93","author":"G Koren","year":"2020","unstructured":"Koren G, Barer Y, Ornoy A (2020) Fetal safety of methylphenidate\u2014A scoping review and meta analysis. Reproductive Toxicol (Elmsford N Y) 93:230\u2013234. https:\/\/doi.org\/10.1016\/j.reprotox.2020.03.003","journal-title":"Reproductive Toxicol (Elmsford N Y)"},{"key":"1450_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fpubh.2018.00057","volume":"6","author":"CL Kuo","year":"2018","unstructured":"Kuo CL, Duan Y, Grady J (2018) Unconditional or conditional logistic regression model for age-matched case\u2013control data? Front Public Health 6:57\u201357. https:\/\/doi.org\/10.3389\/fpubh.2018.00057","journal-title":"Front Public Health"},{"issue":"7","key":"1450_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40263-020-00728-2","volume":"34","author":"L Li","year":"2020","unstructured":"Li L, Sujan AC, Butwicka A, Chang Z, Cortese S, Quinn P, Larsson H (2020) Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS Drugs 34(7):731\u2013747. https:\/\/doi.org\/10.1007\/s40263-020-00728-2","journal-title":"CNS Drugs"},{"issue":"11","key":"1450_CR30","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.4088\/JCP.15m10506","volume":"77","author":"DJ Newport","year":"2016","unstructured":"Newport DJ, Hostetter AL, Juul SH, Porterfield SM, Knight BT, Stowe ZN (2016) Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. J Clin Psychiatry 77(11):1538\u20131545. https:\/\/doi.org\/10.4088\/JCP.15m10506","journal-title":"J Clin Psychiatry"},{"key":"1450_CR31","doi-asserted-by":"publisher","unstructured":"N\u00f6rby U, Winbladh B, K\u00e4ll\u00e9n K (2017a) Perinatal outcomes after treatment with ADHD medication during pregnancy. Pediatrics 140(6). https:\/\/doi.org\/10.1542\/peds.2017-0747","DOI":"10.1542\/peds.2017-0747"},{"key":"1450_CR32","doi-asserted-by":"publisher","unstructured":"N\u00f6rby U, Winbladh B, K\u00e4ll\u00e9n K (2017b) Perinatal outcomes after treatment with ADHD medication during pregnancy. Pediatr (Evanston) 140(6). https:\/\/doi.org\/10.1542\/peds.2017-0747","DOI":"10.1542\/peds.2017-0747"},{"issue":"1","key":"1450_CR33","doi-asserted-by":"publisher","first-page":"F36","DOI":"10.1136\/adc.2008.157305","volume":"95","author":"J Oei","year":"2010","unstructured":"Oei J, Abdel-Latif ME, Clark R, Craig F, Lui K (2010) Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Archives Disease Child - Fetal Neonatal Ed 95(1):F36\u2013F41. https:\/\/doi.org\/10.1136\/adc.2008.157305","journal-title":"Archives Disease Child - Fetal Neonatal Ed"},{"issue":"10","key":"1450_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/jp.2012.59","volume":"32","author":"JL Oei","year":"2012","unstructured":"Oei JL, Kingsbury A, Dhawan A, Burns L, Feller JM, Clews S, Abdel-Latif ME (2012) Amphetamines, the pregnant woman and her children: a review. J Perinatol 32(10):737\u2013747. https:\/\/doi.org\/10.1038\/jp.2012.59","journal-title":"J Perinatol"},{"issue":"4","key":"1450_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40263-018-0505-9","volume":"32","author":"AS Poulton","year":"2018","unstructured":"Poulton AS, Armstrong B, Nanan RK (2018) Perinatal outcomes of women diagnosed with attention-deficit\/hyperactivity disorder: an Australian population-based cohort study. CNS Drugs 32(4):377\u2013386. https:\/\/doi.org\/10.1007\/s40263-018-0505-9","journal-title":"CNS Drugs"},{"issue":"2","key":"1450_CR36","first-page":"200","volume":"233","author":"NS Shah","year":"1978","unstructured":"Shah NS, Yates JD (1978) Placental transfer and tissue distribution of dextro-amphetamine in the mouse. Arch Int Pharmacodyn Ther 233(2):200\u2013208","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"11","key":"1450_CR37","first-page":"1506","volume":"88","author":"P Thaithumyanon","year":"2005","unstructured":"Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S (2005) Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant. J Med Assoc Thai 88(11):1506\u20131513","journal-title":"J Med Assoc Thai"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-024-01450-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-024-01450-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-024-01450-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T12:06:44Z","timestamp":1726488404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-024-01450-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1007\/s00737-024-01450-4","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"19 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was granted for this study by the Department of Health Western Australia Human Research Ethics Committee (RGS0000003029) and the University of Western Australia Human Research Ethics Committee (RA\/4\/20\/5530). Data was de-identified and any outcome with less than five observations was not reported to maintain anonymity. Both ethics committees approved a waiver of consent as the study met the criteria set out in the National Statement on Ethical Conduct in Human Research (Council ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}